# A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

> **NCT07191483** · PHASE2 · RECRUITING · sponsor: **Kynexis B.V.** · enrollment: 150 (estimated)

## Conditions studied

- Cognitive Impairment Associated With Schizophrenia (CIAS)

## Interventions

- **DRUG:** KYN-5356 low dose
- **OTHER:** Placebo
- **DRUG:** KYN-5356 Medium Dose
- **DRUG:** KYN-5356 High Dose

## Key facts

- **NCT ID:** NCT07191483
- **Lead sponsor:** Kynexis B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2025-10
- **Final completion:** 2026-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07191483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07191483, "A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07191483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*